Zynerba Pharmaceuticals Inc expected to post a loss of 22 cents a share - Earnings Preview

Zynerba Pharmaceuticals

11/11/2022 16:06

* Zynerba Pharmaceuticals Inc  ZYNE.OQ   ZYNE.O  is expected
to show no change in quarterly revenue when it reports 
results on November 14 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Zynerba
Pharmaceuticals
Inc is for a loss of 22 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Zynerba
Pharmaceuticals Inc is $7​, above​ its last closing price
of $0.64. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.23       -0.23      -0.24     Missed  -4.8
 Mar. 31 2022  -0.23       -0.23      -0.21     Beat    8.2
 Dec. 31 2021  -0.26       -0.26      -0.22     Beat    16.5​
 Sep. 30 2021  -0.25       -0.25      -0.26     Missed  -3.2
 ​​Jun.        -0.20       -0.24      -0.25     Missed  -5
 30 2021                                                
 Mar. 31 2021  -0.25       -0.25      -0.20     Beat    19.8​
 Dec. 31 2020  -0.29       -0.33      -0.33     Met     -0.4
 Sep. 30 2020  -0.43       -0.43      -0.31     Beat    28.3
 This summary was machine generated November 11 at 16:06 GMT. 
All figures in US dollars  unless otherwise stated